$ALLO
Allogene Therapeutics, Inc.
Runway:7 mo
NasdaqMarket cap: —CIK 0001737287
Upcoming catalysts
0 surfacedNo catalysts surfaced for ALLO yet.
Drug pipeline
Recent & active trials
| NCT | Drug | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06925685 | — | — | Enrolling By Invitation | 2039-01-01 |
| NCT04416984 | ALLO-647 | Phase 2 | Active Not Recruiting | 2029-02-01 |
| NCT07085104 | Cyclophosphamide | Phase 1 | Recruiting | 2028-02-01 |
| NCT06500273 | Fludarabine | Phase 2 | Recruiting | 2027-12-01 |
| NCT04696731 | ALLO-647 | Phase 1 | Active Not Recruiting | 2025-10-01 |
| NCT04093596 | ALLO-647 | Phase 1 | Completed | 2025-01-27 |
| NCT05714345 | ALLO-647 | Phase 2 | Terminated | 2024-02-20 |
| NCT05000450 | ALLO-647 | Phase 2 | Terminated | 2023-10-11 |
| NCT03939026 | ALLO-647 | Phase 1 | Completed | 2021-10-23 |